Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of “Hold” from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX) has been assigned an average recommendation of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $28.20.

Several equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a research report on Monday, November 17th. Weiss Ratings restated a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday, December 1st. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. Finally, Truist Financial lowered their price objective on Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Friday, November 7th.

Insider Buying and Selling at Pacira BioSciences

In other news, insider Jonathan Slonin sold 3,960 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $24.09, for a total value of $95,396.40. Following the sale, the insider directly owned 178,367 shares in the company, valued at approximately $4,296,861.03. This trade represents a 2.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.40% of the company’s stock.

Institutional Trading of Pacira BioSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. PNC Financial Services Group Inc. boosted its position in shares of Pacira BioSciences by 17.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 3,511 shares of the company’s stock worth $84,000 after acquiring an additional 531 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Pacira BioSciences by 31.0% in the 1st quarter. US Bancorp DE now owns 2,270 shares of the company’s stock valued at $56,000 after buying an additional 537 shares in the last quarter. Hantz Financial Services Inc. grew its position in shares of Pacira BioSciences by 175.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock valued at $29,000 after buying an additional 721 shares during the last quarter. Inspire Investing LLC grew its position in shares of Pacira BioSciences by 5.1% in the 3rd quarter. Inspire Investing LLC now owns 17,402 shares of the company’s stock valued at $448,000 after buying an additional 846 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Pacira BioSciences by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company’s stock valued at $677,000 after acquiring an additional 1,165 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Pacira BioSciences Trading Up 1.4%

Shares of NASDAQ PCRX opened at $24.77 on Wednesday. The company has a current ratio of 5.26, a quick ratio of 3.78 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $1.07 billion, a PE ratio of 55.05 and a beta of 0.23. Pacira BioSciences has a twelve month low of $18.17 and a twelve month high of $27.64. The stock has a fifty day simple moving average of $23.09 and a 200-day simple moving average of $24.13.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Thursday, November 6th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. The company had revenue of $179.52 million during the quarter, compared to analysts’ expectations of $182.86 million. Pacira BioSciences had a return on equity of 12.82% and a net margin of 2.99%.Pacira BioSciences’s revenue for the quarter was up 6.5% on a year-over-year basis. During the same period last year, the business posted $0.79 EPS. On average, equities analysts forecast that Pacira BioSciences will post 2.41 earnings per share for the current year.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.